The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 15, 2018

Filed:

Jun. 11, 2010
Applicants:

Yichen LU, Wellesley, MA (US);

Nicholas Kushner, Framingham, MA (US);

Amie Strong, Framingham, MA (US);

Zhenghui Xu, Hainan, CN;

Inventors:

Yichen Lu, Wellesley, MA (US);

Nicholas Kushner, Framingham, MA (US);

Amie Strong, Framingham, MA (US);

Zhenghui Xu, Hainan, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/04 (2006.01); A61K 39/12 (2006.01); C40B 40/10 (2006.01); A01H 5/00 (2006.01); A61K 39/07 (2006.01); A61K 38/16 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01);
U.S. Cl.
CPC ...
A61K 39/07 (2013.01); A61K 38/164 (2013.01); A61K 38/193 (2013.01); A61K 38/2013 (2013.01); A61K 39/00 (2013.01); A61K 39/04 (2013.01); A61K 2039/6037 (2013.01);
Abstract

The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.


Find Patent Forward Citations

Loading…